Stroke & neurological recovery
Acute and rehabilitation-stage stroke research forms the main human evidence base.
Explore the research →NEUROPROTECTION & COGNITIVE RESEARCH
Semax
A brain-focused peptide explored for cognition, focus and neurological recovery, with most human research coming from regional clinical practice.
Stroke researchNeuroprotectionCognition
Regional human studies with limited international validationSmall and open-label human studies report neurological signals, while modern large randomized trials and independent replication remain limited.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
What makes Semax scientifically interesting?
Semax attracts attention around focus, mental clarity and brain recovery. Its links with neuroprotection and the brain's ability to adapt and form connections help explain why interest has grown beyond its original research in people recovering from stroke.
Neuroprotective signalling
Semax is explored for effects on neuronal stress, inflammation and survival pathways.
Explore the research →Attention & cognitive performance
Nootropic interest extends Semax beyond its neurological research origins.
Explore the research →BDNF-related biology
Changes in neurotrophic signalling are often proposed as part of the mechanism.
Explore the research →THE SCIENCE BIT
An ACTH-derived peptide with a neural-signalling story.
Semax was developed from part of ACTH, with added amino acids intended to change its behaviour. Its research explores neurotrophic signalling, inflammatory responses and the way neural cells respond to injury.
BDNF-related effects are a recurring laboratory theme. There is no single, fully established Semax receptor that explains all reported effects, and regional human findings need to be read alongside the study design.
See the studies & trials →- ACTH-derived
- The peptide's starting design
- Neurotrophic signals
- BDNF-related experimental findings
- Stress response
- Neural injury and inflammation
How this connects to the research
Experimental mechanisms with limited regional human evidence.
FROM MOLECULE TO TISSUE
Where Semax connects with the body
These are the tissues and biological systems behind the interest in Semax.
- Brain
- Stroke and cognition research.
- Neurons
- Cell-survival signalling.
- Neural networks
- Attention-related interest.
The research behind the interest
Stroke & neurological recovery
Acute and rehabilitation-stage stroke research forms the main human evidence base.
Small Russian studies reported neurological and functional improvements; study design and generalisability limit certainty.
Early human evidenceExplore the studies →Neuroprotective signalling
Semax is explored for effects on neuronal stress, inflammation and survival pathways.
Animal ischaemia and transcriptomic studies support multiple neuroprotective mechanisms.
Strong preclinical evidenceExplore the studies →Attention & cognitive performance
Nootropic interest extends Semax beyond its neurological research origins.
Direct controlled evidence in healthy people for durable cognitive enhancement is limited.
Limited human evidenceExplore the studies →BDNF-related biology
Changes in neurotrophic signalling are often proposed as part of the mechanism.
Clinical and preclinical studies report associations with BDNF, but biomarker change is not the same as proven cognitive benefit.
Mechanistic + early human evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableSemax in acute hemispheric ischemic stroke ↗
30 treated patients; 80 conventionally treated controls with comparable stroke severity and location
Intranasal12 mg/day for moderate or 18 mg/day for severe stroke5 or 10 days
Adding Semax to intensive therapy was associated with faster regression of cerebral, focal and especially motor disorders.
The small, older regional study does not establish efficacy to modern international trial standards.
Semax during early and late ischemic-stroke rehabilitation ↗
110 people assessed during early or late rehabilitation after ischemic stroke
Intranasal6,000 mcg/dayTwo 10-day courses separated by 20 days
Semax exposure was associated with higher plasma BDNF and improved Barthel and motor-recovery measures.
Subgroup allocation and the regional study setting limit causal certainty and generalisability.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceLimited
2/5 evidence depth
Small regional clinical studies exist, particularly in stroke.
✓
Clinical efficacyLimited
2/5 evidence depth
Positive signals have not been confirmed in large internationally replicated efficacy trials.
◇
Safety evidenceLimited
2/5 evidence depth
Regional medicinal use provides some exposure experience, but long-term use outside indications is not well characterised.
⌁
Preclinical evidenceStrong
4/5 evidence depth
Extensive animal and cellular neuroprotection research supports biological plausibility.
HOW TO READ THESE SCORESStrong preclinical evidence · limited human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPESemaxMechanism → translation → human outcome
Positive regional stroke signals with design limitations
Substantial animal and molecular neurobiology literature
Large blinded international trials and healthy-user data
What this snapshot does—and does not—show
It separates biological plausibility from demonstrated benefit. A compelling mechanism can justify better trials; it cannot substitute for them.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Semax
Community discussion focuses on focus, mental energy, mood and neurological recovery. The human literature is more substantial than for many research peptides, but remains regional and methodologically limited.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Sharper focus for work or study
People are interested in staying with a task, organising thoughts and feeling mentally less foggy. The attraction is a clearer working day rather than simply a noticeable sensation soon after use.
- What makes a report informative
- Task completion, concentration and mental stamina.
- What can muddy the picture
- Sleep, caffeine, stress and workload can change the same outcomes.
Mental energy and resilience under pressure
Some interest concerns motivation, confidence or coping with demanding days. These are subjective experiences that are most useful when tied to a specific situation and a sustained change in function.
- What makes a report informative
- Daily function and whether clarity comes with agitation or poor sleep.
- What can muddy the picture
- A stimulating feeling does not establish a reliable mood or cognitive benefit.
Neurological recovery
Stroke-related studies draw interest from people hoping for brain recovery. Rehabilitation outcomes in a clinical population are a separate question from cognitive enhancement in otherwise healthy adults.
- What makes a report informative
- The diagnosis, rehabilitation programme and measured functional outcome.
- What can muddy the picture
- Regional stroke studies cannot establish a general nootropic effect.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Focus and mental clarity
Healthy-user nootropic use is common in online discussion.
Human findings & limits
Controlled healthy-volunteer evidence for meaningful cognitive enhancement is limited.
Laboratory & animal context
Neurotrophic, inflammatory and monoamine-related mechanisms are explored.
What this means: Popular community use extends beyond the best-studied clinical setting.
Stroke recovery
Semax was developed and studied in neurological care.
Human findings & limits
Small studies report functional signals, but lack large independent replication.
Laboratory & animal context
Animal ischaemia models provide strong biological support.
What this means: Early human evidence worth following, not a replacement for standard stroke treatment.
Mood and resilience
Users sometimes describe greater drive or reduced mental fatigue.
Human findings & limits
These outcomes are not established in robust mood-disorder trials.
Laboratory & animal context
Stress-response and neurotrophic pathways provide hypotheses.
What this means: Anecdotal interest currently exceeds direct clinical evidence.
Intranasal onset and short cycles
People often favour brief nasal-use windows for work, study or training blocks.
Human findings & limits
Published stroke protocols confirm intranasal clinical exposure, but at disease-specific doses and under medical care.
Laboratory & animal context
Animal pharmacology supports a nasal-to-neural research route, without validating retail spray concentration or pump delivery.
What this means: Route familiarity is real; healthy-user dose accuracy and benefit remain uncertain.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDA low community start kept separate from stroke protocols
This example reflects healthy-user discussion around focus. Published stroke research used far higher, disease-specific daily amounts under clinical care.
1Days 1–3
200 mcg / dayAnecdotal intranasal starting amount
2Days 4–7
200–400 mcg / dayOptional divided-use step discussed online
3Days 8–14
Up to 600 mcg / dayUpper end of common community descriptions
4After course
Pause & reviewNo validated nootropic break schedule
What people commonly discuss200–600 mcg/day intranasally for roughly 10–14 days, sometimes split earlier and later in the day.
What remains unvalidatedHealthy-user efficacy, dose-response, pump accuracy and long-term safety are not established. Stroke protocols are not a titration target.
ROUTE & DELIVERYA spray count is not a dose
Delivered micrograms depend on concentration (mcg/mL), pump volume (mL per spray) and the number of sprays. Those figures must be known before a nasal amount can be calculated.
PROFESSIONAL SOURCE CONTEXT
Published post-stroke protocol · 6 mg/day ↗The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
Regional clinical protocols exist, but there is no internationally validated Semax dose for general cognition, focus or wellness.
PUBLISHED HUMAN RESEARCH
View source ↗Acute ischemic-stroke clinical study ↗
30 treated patients in the acute period of hemispheric ischemic stroke
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved 30 treated patients in the acute period of hemispheric ischemic stroke. Route: Given through the nose. The study lasted 5 or 10 days. The figures below describe the research design, not a personal schedule.
| First amount studied | 12 mg/day |
|---|---|
| Later or target amount | 18 mg/day |
| How often? | Daily dose selected by stroke severity |
| How was it given? | Given through the nose |
| How long? | 5 or 10 days |
See the exact study wording +
Start / initial: 12 mg/day
End / target: 18 mg/day
Frequency: Daily dose selected by stroke severity
Route: Intranasal
Study duration: 5 or 10 days
Source: Ashmarin et al., 2001 ↗
Hospital adjunct protocol in acute stroke—not a dose escalation plan and not a healthy-user cognition schedule. Stroke is a medical emergency.
PUBLISHED HUMAN RESEARCH
View source ↗Post-stroke rehabilitation study ↗
110 people in early or late rehabilitation after ischemic stroke
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved 110 people in early or late rehabilitation after ischemic stroke. Route: Given through the nose. The study lasted 10 days on · 20 days off · 10 days on. The figures below describe the research design, not a personal schedule.
| First amount studied | 6 mg/day |
|---|---|
| How often? | Daily during each course |
| How was it given? | Given through the nose |
| How long? | 10 days on · 20 days off · 10 days on |
See the exact study wording +
Start / initial: 6 mg/day
End / target: 6 mg/day
Frequency: Daily during each course
Route: Intranasal
Study duration: 10 days on · 20 days off · 10 days on
Source: Gusev et al., 2018 ↗
A fixed disease-specific course embedded in rehabilitation; it does not validate the much lower amounts discussed for focus or wellness.
COMMUNITY DISCUSSION
Anecdotal / unvalidated for healthy cognitionWhat people commonly discuss
STARTING APPROACHES
For focus or mental energy, community descriptions often begin around 200 mcg intranasally per day and may describe 400–600 mcg/day in divided use.
DURATION / CYCLES
Short 10–14-day trials are more commonly discussed than continuous use.
MAINTENANCE DISCUSSION
People often describe a break and reassessment; no validated nootropic maintenance or tolerance-prevention schedule exists.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Intranasal formulation guide
Human research · stroke-specificPublished human courses were used in stroke care and rehabilitation. They do not establish a healthy-user focus schedule. Enter the delivered amount from the specific formulation; a drop or spray is not a universal dose.
Form and route: Intranasal; concentration and delivery device matter
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Semax
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDSemax
→
OFTEN EXPLORED WITHSemax + Selank
Semax + Selank
→
OFTEN EXPLORED WITHSemax + rehabilitation
Semax + Standard stroke rehabilitation
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
SSEMAX IS USUALLY DISCUSSED AROUNDNeuroprotection, BDNF and neurological recovery
＋The strongest human context is regional stroke research, not routine cognitive enhancement.
PTHE PAIRED APPROACH MAY ADDCalm-focus support or structured rehabilitation
Selank and rehabilitation represent very different pairings; only rehabilitation has an established role in stroke recovery.
＋
OFTEN EXPLORED WITH
Explore →＋Semax + Selank
Semax + SelankWHY IT IS EXPLOREDA common cognitive-wellbeing pairing intended to combine focus and anxiolytic themes.
Combination-specific efficacy and safety have not been established.OFTEN EXPLORED WITH
Explore →Semax + rehabilitation
Semax + Standard stroke rehabilitationWHY IT IS EXPLOREDClinical publications studied Semax as an adjunct to neurological care.
Not a substitute for emergency stroke care or evidence-based rehabilitation.01Separate wellness from stroke care
A community nootropic stack is not comparable with an adjunct used in medical rehabilitation.
02Watch overlapping CNS effects
Stimulation, sleep and mood effects may change when neuroactive compounds are combined.
03Demand direct evidence
Separate component studies cannot establish better cognition or safer recovery together.
Safety context
SAFETY & UNCERTAINTY
Regional use does not remove evidence gaps
01ENCOURAGING CONTEXTHuman intranasal exposure has been reported
Regional stroke studies provide more clinical context than a purely animal research programme.
02THE CLINICAL BOUNDARYStroke evidence belongs to stroke care
A stroke is an emergency. Semax must never delay emergency assessment, reperfusion treatment or evidence-based rehabilitation.
03WHAT REMAINS UNKNOWNHealthy-user and long-term neuropsychiatric safety
Sleep, mood, stimulation, medication interactions and repeated-course safety are not well characterised.
What the current evidence saysNasal irritation, headache, sleep or mood effects, interactions and product-concentration errors are relevant practical concerns. Long-term safety for healthy-user cognitive enhancement has not been established.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Unknown concentration or pump volume creates a dose-accuracy problem before the peptide itself is considered.
Headache, irritability, unusual mood change or persistent insomnia are reasons to stop and seek advice.
Effects alongside stimulants, antidepressants, sedatives or other nootropics are not adequately mapped.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
5 sourcesSources used on this profile
Bibliographic recordSemax in acute hemispheric ischemic strokePubMed ↗Original publicationSemax during early and late ischemic-stroke rehabilitationJournal / DOI ↗Bibliographic recordSemax during early and late ischemic-stroke rehabilitationPubMed ↗Professional sourceUnited KingdomMHRA products database ↗Professional sourceUnited StatesFDA Drugs@FDA database ↗
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine is represented on this profile
Semax is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗No FDA-approved therapeutic product identified
Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.